Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Oct 19;85(8):1147-52.
doi: 10.1054/bjoc.2001.2051.

Expression of hMLH1 is inactivated in the gastric adenomas with enhanced microsatellite instability

Affiliations
Free PMC article

Expression of hMLH1 is inactivated in the gastric adenomas with enhanced microsatellite instability

M J Baek et al. Br J Cancer. .
Free PMC article

Abstract

Microsatellite instability (MSI) and frameshift mutations in the genes containing coding nucleotide repeats have been reported in a subset of gastric adenomas, however the inactivation profiles of DNA mismatch repair genes in MSI-positive gastric adenomas have not been characterized. To address the origin of MSI in gastric adenomas, expressions of hMLH1 and hMSH2 were explored in 86 gastric adenomas. Gastric carcinomas, of which 16 were MSI-positive and 22 MSI-negative, were used as controls. MSI was found in 15 (17%) of gastric adenomas. Absent or decreased hMLH1 expression by immunohistochemistry was noted in most of the MSI-positive adenomas (13/15, 87%) and carcinomas (14/16, 88%), and all of these tumours showed methylation of the hMLH1 gene promoter. In contrast, rare inactivation of hMLH1 expression was found in MSI-negative adenomas (3/71, 4%) and carcinomas (2/22, 9%). Intense expression of hMSH2 gene product was observed in most of the gastric adenomas and carcinomas regardless of MSI status. These findings indicate that the inactivation of hMLH1 gene expression by promoter methylation is an early event and might be the origin of MSI-positive gastric adenomas.

PubMed Disclaimer

References

    1. Cancer Res. 1999 Nov 1;59(21):5438-42 - PubMed
    1. Cancer Res. 1999 May 1;59(9):2029-33 - PubMed
    1. Int J Cancer. 2000 Jan 1;85(1):50-3 - PubMed
    1. Lab Invest. 1999 Sep;79(9):1113-20 - PubMed
    1. Int J Cancer. 1999 Oct 29;83(3):309-13 - PubMed

Publication types